Adjusting alcohol-seeking behavior

Aptinyx presents data demonstrating robust activity of NYX-783 in multiple models
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
EVANSTON, Ill.—Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced earlier this summer the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and relapse-like behavior in multiple models of alcohol use disorder.
“Given the increasingly recognized societal impact of substance abuse, and the lack of safe and effective therapies, we are very encouraged by the activity demonstrated by NYX-783 in these preclinical models of alcohol use disorder,” said Dr. Cassia Cearley, vice president of research at Aptinyx. “Together with the favorable safety and tolerability profile already demonstrated in a Phase 1 study, these data strongly support the development of NYX-783 in substance abuse conditions. With NYX-783 currently in Phase 2 development as a therapy for PTSD [post-traumatic stress disorder], the results from these preclinical studies support its potential to treat one of the more prevalent comorbidities associated with PTSD, and expand the potential indications in which the mechanism of NYX-783 may have relevance.”
Continue reading below...
Reliable fluid biomarkers strategies for clinical neuroscience research
WebinarsReliable fluid biomarker strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Read More
In the recent preclinical studies, behavior was assessed in two different models of alcohol use disorder in which animals were trained to self-administer ethanol through lever pressing. In the first model, an alcohol dependence model, alcohol dependence was induced in rats by exposing animals to ethanol vapor, with exposure to air used as a comparative control. After alcohol dependence was established, rats were dosed with either 0.1 mg/kg NYX-783, 6 mg/kg NYX-783 or vehicle one hour prior to the first extinction session.
Three weeks after extinction, rats were evaluated for relapse-like behavior after re-exposure to alcohol associated cues. In the second model, a stress-induced alcohol-seeking model, rats were exposed to a stressor prior to being trained to self-administer ethanol. Stress exposure increased alcohol-seeking behavior and rendered rats resistant to extinction of alcohol-seeking behavior. This approach models the influence of PTSD on substance abuse. Animals were then evaluated during and after the same extinction paradigm as described in the alcohol dependence model.
Continue reading below...
An illustration of interconnected neurons glowing with orange light, representing neural activity
WebinarsUnderstanding neuroinflammation in Parkinson's disease
Explore the role and cellular mechanisms of neuroinflammation in Parkinson’s disease.
Read More
In both the alcohol dependence model and the stress-induced alcohol seeking model, animals dosed with NYX-783 prior to extinction demonstrated a significantly more rapid elimination of alcohol-seeking behavior as compared to vehicle. Animals dosed with NYX-783 prior to extinction also demonstrated significantly less relapse-like behavior when exposed to alcohol-associated cues in the alcohol dependence model or stress-associated cues in the stress-induced alcohol-seeking model. In the stress-induced alcohol-seeking model, animals that were only dosed with NYX-783 prior to re-exposure to the stress-associated cue also demonstrated significantly less relapse-like behavior when compared to vehicle-treated rats.

Related Topics

Published In

Volume 15 - Issue 9 | September 2019

September 2019

September 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D molecular visualization of antibody-like protein structures with attached yellow payloads floating against a dark, space-like background.
Evolving approaches to conjugation chemistry and linker–payload design are helping address persistent challenges in bioconjugate development.
Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue